A B S T R A C T The metabolism of radioactive testosterone simultaneously administered intravenously and either orally or percutaneously has been studied in seven patients with the syndrome of testicular feminization and compared with that of normal males and females. This investigation was carried out in order to determine the relative contribution to urinary 17-oxo and 17p-hydroxy androstane steroids of labeled testosterone, according to its mode of administration. In normal males the yields of urinary 5a-androstane-3a,17,-diol (androstanediol) originating from either an intravenous or a percutaneous dose of testosterone were respectively 3 and 6 times higher than those arising from an oral dose which perfuses the liver directly. These data indicate that in normal males, testosterone might be 5a-hydrogenated outside the liver. By contrast in patient with feminizing testes, because the contribution to androstanediol of radioactive testosterone is identical whatever its mode of administration, the extrahepatic 5a-reduction of this substrate seems very unlikely.
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The metabolic abnormalities observed in patients with testicular feminization syndrome may be reproduced in normal males by estrogen treatment. Nevertheless, the sensitivity of the patients to estrogen seems to be 10 times greater than that of normal males. This sensitivity was appreciated from the reduction of radioactive testosterone intravenously injected to urinary 17P-hydroxy-5a-androstan-3-one and androstanediol and also from the level of plasma binding for testosterone. This level was significantly higher (P < 0.05) in patients with feminizing testes than in normal males. The level increased dramatically after administration of a low dose of estrogen whereas this effect was not observed in normal males under the same experimental conditions.
In light of these results the defect of extrahepatic 5a-reduction of testosterone observed in patients with Part of this work has been published as a preliminary communication (14) .
INTRODUCTION
It is well known that the syndrome of testicular feminization develops in the presence of blood testosterone1 levels sufficiently to cause virilization in normal individuals (1) (2) (3) . This observation suggests that the clinical manifestations of the syndrome are related to a defect in androgen action. Recently, we have reported that male sex differentiation is partly associated with a stimulation of enzymes allowing the ring A reduction of testosterone to 17P-hydroxyandrostane steroids ( Fig. 1 ) (4, 5) . When normal males and hirsute females are intravenously injected with radioactive testosterone, the contribution of this precursor to urinary 5a-and 5P-androstane-3a, 17f-diol is higher than in normal females and hypogonadal males with gonadotrophin deficiency. The treatment of the latter patients by chorionic gonadotrophin restores a normal male metabolic pattern. On the contrary, the administration of synthetic estrogens to normal males decreases the excretion of urinary metabolites originating from the ring A reduction of testosterone (6) . In all these situations the yield of urinary 17P-hydroxyandrostane steroids arising from testosterone is correlated with the concentration of this an-'The following trivial names have been used: T = testosterone; androstanolone = 17#-hydroxy-Sa-androstan-3-one; androstenedione = androsta4-ene-3,17-dione; androstanedione = 5a-androstane-3,17-dione; androsterone (A) = 3a-hydroxy-5a-androstan-17-one; isoandrosterone = 3pi-hydroxy5a-androstan-17-one; 5f8-androsterone (5,8-A) = 3a-hydroxy5p-androstan-17-one; androstanediol (Adiol) = 5a-androstane-3a,17fl-diol; Sp-androstanediol (5p-Adiol) = 5p-androstane-3a,17,B diol; androstanediols = diols = androstanediol + 5,B-androstanediol.
The Journal of Clinical Investigation Volume 49 1970 31 drogen in biological fluids. This is not the case in patients with testicular feminization syndrome in whom, despite normal male testosterone secretion, the conversion of testosterone to androstanediols occurs at a very low rate (5, 7) .
These clinical data are ascertained by the fact that labeled testosterone is not only taken up by accessory sex tissues but is also quickly metabolized in these tissues, particularly to 17P-hydroxy-5a-androstane metabolites (8, 9) which are known to be very potent androgens (10, 11) . More recently, it has been reported that 17,8-hydroxy-5a-androstan-3-one (androstanolone) is the only metabolite present in the prostatic nuclei after intravenous administration of radiocative testosterone to rats or after incubation of rat prostate with the same precursor (12, 13 (14) . The urine was collected over 3 days after the administration of tracers. All these experiments were done under the same experimental conditions in normal males and females. In a postpubertal case (J. Q.) an intravenous dose of testosterone-'4C was injected before and after castration. The first month was without hormonal treatment. After that, there was a daily injection of 25 mg of testosterone propionate for 30 days and then an oral administration of 5 mg of diethylstilbestrol for 20 days.
In addition, 0.5 gc of testosterone-j'C and 3.04.6 uc of testosterone-17a-8H, synthesized in the laboratory as previously described (15) , were injected into one patient with testicular feminization syndrome and into one normal volunteer male before and after treatment with 50 mg of diethylstilbestrol daily for 20 days. Another patient with testicular feminization and the same normal male were injected, under the same experimental conditions, with 1.0 /Ac of testosterone-"C and 10-11 ,uc of 17,8-hydroxy-5a-androstan-3-one-'H (androstanolone) made in the laboratory according to the previously described procedure (16) .
The recovery of radioactivity from aliquots of urine collections as androsterone (sulfate + glucuronide), 5,8-androsterone (sulfate + glucuronide), androstanediol, and 5p8-androstanediol (glucuronides) was measured. Details of the analysis procedure are as previously described (5, 15 in a batchwise fashion. With such a technique, it is possible under precise experimental conditions to determine the amount of serum proteins necessary to obtain 50% of binding with a given and very low concentration of radioactive steroid (1 X 10' mole). The relative binding activity may be expressed as Sb/(Su X P), Sb and Su representing respectively the bound and unbound steroid concentration and P, the amount of protein.
When Sb/Su = 1.0, the binding affinity is equal to 1/P. Expressed in liters per gram, this value is a good index of the relative binding affinity of testosterone for various sera.
This determination was performed in six cases of testicular feminization, five normal males, and eight females. In addition, this was repeated in four patients with feminizing testes and two volunteer normal males after administration of 5 mg of diethylstilbestrol daily for 20 days. RESULTS Simultaneous administration of testosterone-H orally and testosterone-14C intravenously (Table I , Fig. 2 ). In normal males, females, or patients with feminizing testes, the recoveries of urinary 5fP-androsterone originating from radioactive testosterone either orally or intravenously administered were not significantly different (P < 0.50 for the three groups of-subjects). Similarly in males, the per cent conversions of the two doses of testosterone to 5f-androstanediol did not differ significantly (P < 0.10). However in females, there was less 5fi-androstanediol recovered in urine from the intravenously injected testosterone (1.55 +0.15% SE) than from the orally administered compound (1.88 ±0.22% SE). These values are significantly different (P < 0.05). In the case of patients with feminizing testes, the difference was more significant (P <0.01) since 59-androstanediol arising from intravenous testosterone (1.29 +0.42% SE) was half that arising from testosterone orally administered (2.23 ±0.43% SE). These differ- As regards androstanediol, the per cent conversion of the intravenously injected dose of testosterone was 1.60 ±0.20% SE in males. This value was significantly higher (P < 0.05) than the per cent conversion of the oral dose of testosterone to the same metabolite (0.68 ±0.17% SE). In females the difference was less important but still significant (P < 0.05). In patients with feminizing testes the yields of urinary androstanediol originating from either the intravenously or the orally administered testosterone were respectively 0.50 ±0.15%
A 5A-AdiaI Adiol T-14-C intravenously T-3H orally In a prepuberal patient (case M.B., Table I , Fig. 4 ), there was a greater proportion of androstanediol arising from the intravenously injected testosterone (2.41 %) than from the orally administered precursor (0.77%).
The R value of androstanediol was therefore elevated (3.10). This pattern is quite similar to that observed in normal males and very different from that of patients studied after puberty. In addition when the prepuberal patient was treated with 1 mg of diethylstilbestrol for only 10 days, there was a dramatic decrease in the contribution to androstanediol of testosterone injected in the peripheral circulation and not of testosterone orally administered. The relative contribution to androstanediol of the two doses of testosterone (R = 1.50) was then comparable to that of adult patients.
Simultaneous administration of testosterone-'H by percutaneous route and of testosterone-'4C by intravenous injection (Table II) . Only 4-6% of radioactive testosterone percutaneously administered was recovered in the urine as 17-ketosteroids and androstanediols. However, as long as the radioactive doses of testosterone were administered with an elevated 'H: 'C ratio (6.6-8.8), it was possible to determine with good precision the 'H: SC ratio in the recovered urinary metabolites. In normal males, females, and patients with feminizing testes, the 'H: "C ratios of androsterone, 5j3-androsterone, and 5f-androstanediol were very similar for all subjects. However in males, the 'H: "C ratios of androstanediol were 3 times the 'H: 'C ratios of other metabolites. This difference was less important in females whereas in patients with feminizing testes the 'H: "C ratios of androstanediol did not differ from those of other metabolites. These data are emphasized by comparing for each group of subjects the proportion of percutaneous compared to intravenous dose of radioactive testosterone excreted as the same metabolite, i.e., R value. This R value was calculated for each metabolite by dividing the "C: 'H ratio of the injected compounds by the "C: 'H ratio in a purified sample of the metabolite (Fig. 2) . The values obtained have been arbitrarily multiplied by 10 because the radioactivity recovered in urinary metabolites originating from percutaneous testosterone-'H was only the 8th to the 10th part of radioactivity recovered in the metabolites arising from testosterone-J'C intravenously injected. Then, it was possible to compare the mean R values of the same metabolites arising from a combined dose of testosterone administered either percutaneously and intravenously or intravenously and orally.
Moreover, the contribution to androstanediol of each administered dose of testosterone was also appreciated by comparing the different 5a: 5fi ratios calculated from the radioactivity recovered in the urine as androstanediols (Fig. 3) . In males the mean 5a: 5f ratio of androstanediols arising from the percutaneous dose of testosterone is 3 and 6 times the corresponding ratio of diols originating respectively from the intravenous and the oral dose. In patients with feminizing testes the 5a: 5p ratios of diols are very similar when testosterone is either intravenously or percutaneously administered. Longitudinal studies in a case of testicular feminimtion after castration (Fig. 4) . After castration of the patient J.Q., there was a significant increase in the conversion rate to androstanediols (especially to the 5a-compound) of radioactive testosterone intravenously injected. The yields of urinary diols were then similar to those of normal males. In addition, the treatment of this castrated patient with testosterone propionate did not modify the conversion rate of testosterone to diols, whereas his treatment with 5 mg of diethylstilbestrol for 20 days was followed by a fall in urinary metabolites originating from the ring A reduction of testosterone.
Metabolism of 17a-'H4-"4C-testosterone (Table III) .
In the normal male studied, the * Testosterone isolated in the glucuronide fraction of the urine. This ratio was obtained from a purified sample of the urinary metabolite. § After treatment with 50 mg of diethylstilbestrol daily for 20 days. same proportions since the 'H: 14C ratios of these metabolites are very close. In the patient with feminizing testes as in the male treated with diethylstilbestrol, practically no androstanolone glucuronide was recovered in the urine from the injected radioactive testosterone, and the 'H: 14C ratios of urinary androstanediol and androstanolone glucuronides were very different. These results confirm that in the latter subjects androstanolone is not an important metabolic intermediate between testosterone and androstanediol.
Testosterone binding levels in serum (Fig. 5) . The relative binding affinity of serum protein for testosterone was significantly higher in patients with feminizing testes than in normal males (P < 0.05) and very similar to that of normal females. The mean values (in liters/gram of serum protein) were, respectively, 1.56 +0.59 SE for testicular feminization syndrome cases (n = 6 determinations), 0.90 0.21 SE is 2 times higher than that originating from testosterone which enters the liver directly by the portal vein, whereas the yield of androstanediol arising from testosterone percutaneously applied is 2.5 times higher than that arising from testosterone injected in the peripheral circulation. These results are in agreement with in vitro data suggesting that a characteristic of cutaneous testosterone metabolism is the stereospecific reduction of the ring A leading to the formation of 5a-androstane steroids (18, 19) . The actual importance of testosterone metabolism by an organ as large as the skin is difficult to establish. However, from our in vivo results it may be postulated that at least 50% of androstanediol recovered in the urine of males arise from the 5a-reduction of testosterone outside the liver. Contrary to what is observed in males, the extrahepatic 5a-reduction of testosterone seems to be negligible in patients with feminizing testes since identical yields of urinary androstanediol result whatever the mode of administration of radioactive testosterone. These in vivo data are in agreement with those obtained by Wilson and Walker (20) and by Northcutt, Island, and Liddle (21) from in vitro experiments. From these reports, there could be a lack of testosterone 5a-reduction in the skin of patients with testicular feminization syndrome. Furthermore in the light of our results, the hepatic 5p8-reduction of testosterone seems to be hampered if one considers the low yield of 5,8-androstanediol originating from testosterone intravenously injected to these patients.
Estrogens seem to be importantly involved in the metabolic abnormalities observed in patients with testicular feminization syndrome. In subjects without estrogen production, such as prepuberal or castrated patients, the yield of androstanediol arising from testosterone is comparable to that of normal males. In males it is possible to inhibit with diethylstilbestrol the reduction of testosterone to androstanolone and androstanediol (6) . In other words, testosterone is metabolized in the same way in males treated with diethylstilbestrol as it is in patients without estrogen deprivation. However, the inhibitory effect of estrogen upon testosterone 5a-reduction may be obtained in castrated and prepuberal patients with a dose which is 10 times smaller than in normal males. One can therefore wonder if the decrease in testosterone 5a-reduction observed in patients with feminizing testes reflects an enzymatic impairment or is only the result of the abnormal sensitivity of a specific enzyme to estrogens originating either directly from testes or indirectly from the peripheral conversion of testosterone and androstenedione (22, 23) . Estrogen may act by (a) inhibition of the enzyme allowing in target cells the hydrogenation of testosterone to androstanolone as the nuclear enzyme described by Bruchovsky and Wilson (12) or (b) increase of specific plasma protein binding testosterone (24, 25) so that almost no unbound testosterone may be available in target cells for 5ca-reduction. This last hypothesis is sustained by the high binding levels for testosterone observed in the plasma of patients, and furthermore, seems very consistent regarding the hepatic 5P-reduction of testosterone which is very low when the steroid is injected intravenously but is normal when testosterone is orally administered. In the case of oral administration, testosterone probably enters the liver before being bound to a specific protein (26) contrarily to what is observed when the steroid is injected in the peripheral circulation. Although data concerning estrogen production in patients with feminizing testes do not permit a firm conclusion (1, 27, 28) , it seems likely that this production does not exceed that of normal males. Thus, there seems to exist in subjects with testicular feminization syndrome an abnormal synthesis of plasma-binding protein under the effect of circulating estrogens. This hypothesis is supported by the fact that with the same low dose of diethylstilbestrol plasma-binding levels for testosterone were not modified in males but did increase dramatically in patients with feminizing testes. That castrated patients do not respond to testosterone does not exclude such an hypothesis. In males as in patients with feminizing testes, the main part of circulating estrogens originates from peripheral conversion of testosterone (22, 23) . Therefore, treatment with testosterone of castrated patients may maintain an elevated binding level in plasma.
However, it has not actually been proven that the synthesis of specific protein(s) binding testosterone in plasma is altered in testicular feminization syndrome. Thus, further investigation must be undertaken before it can be said if the metabolic abnormalities observed in patients with this genetic disease are due to the absence of specific enzyme(s), or to an elevated binding of -testosterone to proteins which prevents the penetration of this androgen in target cells, or to both. Furthermore, it has not definitively been proven that the lack of masculinization observed in patients with feminizing testes depends upon the absence of biotransformation of testosterone to androstanolone in target tissues.
